Please login to the form below

Not currently logged in
Email:
Password:

omecamtiv

This page shows the latest omecamtiv news and features for those working in and with pharma, biotech and healthcare.

FDA fast-tracks Jardiance for heart failure review

FDA fast-tracks Jardiance for heart failure review

year. Other contenders looking to meet the needs of heart failure patients include Amgen and Servier, whose omecamtiv mecarbil, recently passed a futility review in its phase 3 study.

Latest news

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv mecarbil for heart failure (phase III).

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    In collaboration with Cytokinetics, Amgen is developing omecamtiv mecarbil, an activator of cardiac myosin that is designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    100. ‡‡Servier / Amgen .  Cardiovascular collaboration, licence and option. Procoralan (ivabradine, approved), S38844 (p2), omecamtiv mecarbil (p2). ... rights in Europe for omecamtiv mecarbil. †

  • Pharma deals during July 2013 Pharma deals during July 2013

    the US, and Servier receives an option to omecamtiv mecarbil for Europe. ... Omecamtiv mecarbil is currently in phase II trials for acute and chronic heart failure and is the most advanced drug candidate coming out of Amgen's collaboration with

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    129. Cytokinetics / Amgen. Extension of existing licence to Japan. Small molecules to activate heart muscle, including omecamtiv mecarbil (phase II).

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...

Infographics